MedStar Authors catalog › Details for: Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.
Normal view MARC view ISBD view

Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.

by Baker, Nevin C; Lipinski, Michael J; Lhermusier, Thibault; Waksman, Ron.
Citation: Circulation. 130(15):1287-94, 2014 Oct 7..Journal: Circulation.ISSN: 0009-7322.Full author list: Baker NC; Lipinski MJ; Lhermusier T; Waksman R.UI/PMID: 25287768.Subject(s): *Acute Coronary Syndrome/pc [Prevention & Control] | Clinical Trials Data Monitoring Committees | *Drug Approval | Hemorrhage/ep [Epidemiology] | Humans | Lactones/ae [Adverse Effects] | *Lactones/tu [Therapeutic Use] | *Plaque, Atherosclerotic/pc [Prevention & Control] | Platelet Aggregation Inhibitors/ae [Adverse Effects] | *Platelet Aggregation Inhibitors/tu [Therapeutic Use] | Pyridines/ae [Adverse Effects] | *Pyridines/tu [Therapeutic Use] | Receptor, PAR-1/ai [Antagonists & Inhibitors] | Risk Assessment | United StatesInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): CongressesOnline resources: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1161/CIRCULATIONAHA.114.011471 (Click here) Abbreviated citation: Circulation. 130(15):1287-94, 2014 Oct 7.Local Holdings: Available online from MWHC library: 1950 - present, Available in print through MWHC library: 1999 - 2006.

Powered by Koha